850142-79-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-propoxypyridine is utilized as a building block in organic synthesis, particularly for the preparation of pharmaceuticals. Its unique structure and reactivity contribute to the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Bromo-2-propoxypyridine is employed as a key intermediate for the synthesis of various agrochemicals. Its role in the production of pesticides and other agricultural chemicals is significant for enhancing crop protection and yield.
Used in Fine Chemicals Production:
5-Bromo-2-propoxypyridine is also used in the synthesis of fine chemicals, which are high-purity chemicals used in various industries, including fragrances, dyes, and specialty chemicals. Its versatility in reactions allows for the creation of complex and high-value products.
Used in Research and Development:
5-Bromo-2-propoxypyridine is a common component in research and development laboratories, where it is used as a key intermediate in the synthesis of new and complex molecules. Its presence in the lab setting is crucial for advancing scientific knowledge and innovation in chemical synthesis.

Upstream product

• 71-23-8 propan-1-ol 
• 223463-13-6 2-iodo-5-bromopyridine 
• 766-11-0 5-bromo-2-fluoropyridine 
• 53939-30-3 5-bromo-2-chloropyridine 
• 39856-50-3 5-bromo2-nitropyridine 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 1300728-38-4 N-phenyl-6-propoxypyridin-3-amine 
• 1300728-30-6 N-(2-chlorophenyl)-6-propoxypyridin-3-amine 
• 1417655-93-6 C₂₀H₂₄N₂O₃ 
• 1150114-50-3 6-propoxypyridine-3-boronic acid 

Relevant academic research and scientific papers

Nucleophilic C-H Etherification of Heteroarenes Enabled by Base-Catalyzed Halogen Transfer

We report a general protocol for the direct C-H etherification of N-heteroarenes. Potassium tert-butoxide catalyzes halogen transfer from 2-halothiophenes to N-heteroarenes to form N-heteroaryl halide intermediates that undergo tandem base-promoted alcohol substitution. Thus, the simple inclusion of inexpensive 2-halothiophenes enables regioselective oxidative coupling of alcohols with 1,3-azoles, pyridines, diazines, and polyazines under basic reaction conditions.

ALKYNE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

Provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof, wherein A, B, R 1, R 2, m and n are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: Study of 6-substituted pyridine-3-boronic acid derivatives

In response to the extensive use of antibiotics, bacteria have evolved numerous mechanisms of defense against antimicrobial agents. Among them, extrusion of the antimicrobial agents outside the bacterial cell through efflux pumps is a major cause of concern. At first limited to one or few structurally-related antibiotics, bacterial resistance have then progressed towards cross-resistance between different classes of antibiotics, leading to multidrug-resistant microorganisms. Emergence of these pathogens requires development of novel therapeutic strategies and inhibition of efflux pumps appears to be a promising strategy that could restore the potency of existing antibiotics. NorA is the most studied chromosomal efflux pump of Staphylococcus aureus; it is known to be implied in resistance of Methicillin-resistant S. aureus (MRSA) strains against a wide range of unrelated substrates, including hydrophilic fluoroquinolones. Starting from 6-benzyloxypyridine-3-boronic acid I that we previously identified as a potential inhibitor of the NorA efflux pump against the NorA-overexpressing S. aureus 1199B strain (SA1199B), we describe here the synthesis and biological evaluation of a series of 6-(aryl)alkoxypyridine-3-boronic acids. 6-(3-Phenylpropoxy)pyridine-3-boronic acid 3i and 6-(4-phenylbutoxy)pyridine-3-boronic acid 3j were found to potentiate ciprofloxacin activity by a 4-fold increase compared to the parent compound I. In addition, it has been shown that both compounds promote Ethidium Bromide (EtBr) accumulation in SA1199B, thus corroborating their potential mode of action as NorA inhibitors.

New Positive allosteric modulators of nicotinic acetylcholine receptor

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.

1-‘2-(4-HYDROXYPHENYL)-2-HYDROXYETHYL!-PIPERIDIN-4-OL COMPOUNDS AS NMDA RECEPTOR ANTAGONISTS

This invention provides a compound of the formula (I), wherein R1 and R2 independently represents a hydrogen atom or the like; R3 represents an aryl group having from 6 to 10 ring carbon or the like; said aryl groups havin

FUSED LACTAM COMPOUNDS

This invention provides a compound the formula (I), wherein R1 represents an aryl group having from 6 to 10 ring carbon atoms etc.; R2 represents a hydrogen atom etc., n epresents 0, 1 or 2; said heteroaryl group is unsubstituted or